{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:47:52Z","timestamp":1761763672494},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2000,4]]},"DOI":"10.1053\/ctrv.1999.0163","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T11:23:34Z","timestamp":1027682614000},"page":"81-89","source":"Crossref","is-referenced-by-count":18,"title":["Adjuvant interferon-alpha in malignant melanoma: current status"],"prefix":"10.1053","volume":"26","author":[{"given":"B.W.","family":"Hancock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/ctrv.1999.0163_RF1","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/jnci\/87.22.1710","article-title":"Randomised trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study","volume":"87","author":"Meyskens","year":"1995","journal-title":"J Nat Cancer Inst"},{"key":"10.1053\/ctrv.1999.0163_RF2","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1002\/1097-0142(19841215)54:12<2844::AID-CNCR2820541205>3.0.CO;2-Q","article-title":"Phase II study of recombinant leukocyte A interferon (r-IFN A) in disseminated malignant melanoma","volume":"54","author":"Creagan","year":"1984","journal-title":"Cancer"},{"key":"10.1053\/ctrv.1999.0163_RF3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.1984.2.9.1002","article-title":"Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma","volume":"2","author":"Creagan","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF4","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/1097-0142(19870201)59:3+<638::AID-CNCR2820591312>3.0.CO;2-0","article-title":"Three consecutive phase II-studies of recombinant interferon alpha-2a in advanced malignant melanoma","volume":"59","author":"Creagan","year":"1987","journal-title":"Cancer"},{"key":"10.1053\/ctrv.1999.0163_RF5","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.1987.5.8.1240","article-title":"Clinical evaluation of recombinant interferon alpha-2a (Roferon-A) in metastatic melanoma using two different schedules","volume":"5","author":"Legha","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF6","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/bjc.1985.127","article-title":"Effects of recombinant leucocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma","volume":"51","author":"Hersey","year":"1985","journal-title":"Br J Cancer"},{"key":"10.1053\/ctrv.1999.0163_RF7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00000421-199012000-00004","article-title":"Phase II study of recombinant alpha-interferon in malignant melanoma","volume":"13","author":"Neefe","year":"1990","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/1097-0142(19860715)58:2<215::AID-CNCR2820580202>3.0.CO;2-P","article-title":"Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma","volume":"58","author":"Dorval","year":"1986","journal-title":"Cancer"},{"key":"10.1053\/ctrv.1999.0163_RF9","first-page":"250","article-title":"Role of recombinant interferon-alpha-2 in treatment of advanced malignant melanoma","volume":"7","author":"Mughal","year":"1988","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF10","first-page":"281","article-title":"Interferon-alpha-2b (rIFN-alpha-2b) alone or in combination with DTIC in metastatic melanoma (MM). Compiled Data","volume":"9","author":"Mickiewicz","year":"1990","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7326\/0003-4819-103-1-32","article-title":"Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers","volume":"103","author":"Kirkwood","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1053\/ctrv.1999.0163_RF12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0171-2985(86)80109-7","article-title":"Treatment of metastatic malignant melanoma with recombinant interferon alpha 2","volume":"172","author":"Robinson","year":"1986","journal-title":"Immunobiology"},{"key":"10.1053\/ctrv.1999.0163_RF13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00396385","article-title":"Phase II trial of recombinant leukocyte A interferon in advanced malignant melanoma","volume":"113","author":"Elsasser-Beile","year":"1987","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF00390040","article-title":"Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma","volume":"113","author":"Steiner","year":"1987","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jir.1986.6.1","article-title":"Phase II study of recombinant alpha 2-interferon in advanced malignant melanoma","volume":"6","author":"Coates","year":"1986","journal-title":"J Interferon Res"},{"key":"10.1053\/ctrv.1999.0163_RF16","series-title":"Diagnosis and Management of Melanoma in Clinical Practice.","first-page":"135","article-title":"Systemic treatment of metastatic malignant melanoma","author":"Sheridan","year":"1992"},{"key":"10.1053\/ctrv.1999.0163_RF17","first-page":"24","article-title":"The role of interferon alfa in the treatment of metastatic melanoma","volume":"24","author":"Legha","year":"1997","journal-title":"Sem Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF18","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/bjc.1998.215","article-title":"Adjuvant therapy for melanoma: how should we respond to high-dose interferon?","volume":"77","author":"de Takats","year":"1998","journal-title":"Cancer"},{"key":"10.1053\/ctrv.1999.0163_RF19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(94)90030-2","article-title":"Results of adjuvant interferon study in WHO melanoma programme","volume":"343","author":"Cascinelli","year":"1994","journal-title":"Lancet"},{"key":"10.1053\/ctrv.1999.0163_RF20","first-page":"410","article-title":"Evaluation of efficacy of adjuvant rIFN\u03b1 2 \u03b1 in melanoma patients with regional node metastases","volume":"14","author":"Cascinelli","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF21","unstructured":"Cascinelli, N. Data presented at 3rd International Conference on Adjuvant Therapy of Malignant Melanoma. London, 1999"},{"key":"10.1053\/ctrv.1999.0163_RF22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Co-operative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF23","first-page":"537a","article-title":"Preliminary analysis of the E1690\/S9111\/C9190 Intergroup postoperative adjuvant trial of high- and low-dose IFN\u03b12b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma","volume":"18","author":"Kirkwood","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF24","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(97)12445-X","article-title":"Randomised trial of interferon \u03b1-2a as adjuvant therapy in resected primary melanoma thicker than 1\u20135 mm without clinically detectable node metastases","volume":"351","author":"Grob","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/ctrv.1999.0163_RF25","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1200\/JCO.1998.16.4.1425","article-title":"Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma","volume":"16","author":"Pehamberger","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF26","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.1995.13.11.2776","article-title":"Randomised, surgical adjuvant trial of recombinant interferon-alfa-2a in selected patients with malignant melanoma","volume":"13","author":"Creagan","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF27","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/S0959-8049(99)80697-2","article-title":"Adjuvant trial in melanoma patients comparing rIFN-\u03b1 to rIFN-\u03b3 to Iscador to a control group after curative resection of high risk primary (>3 mm) or regional lymphnode metastasis (EORTC 18871)","volume":"35, Supplement 4","author":"Kleeberg","year":"1999","journal-title":"The European Journal of Cancer"},{"key":"10.1053\/ctrv.1999.0163_RF28","unstructured":"Personal communication Cornbleet."},{"key":"10.1053\/ctrv.1999.0163_RF29","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.1996.14.10.2666","article-title":"Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Co-operative Oncology Group study","volume":"14","author":"Cole","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF30","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1200\/JCO.1997.15.6.2351","article-title":"Economic analysis of adjuvant interferon-alfa 2b in high risk melanoma based on projections from Eastern Co-operative Oncology Group 1684","volume":"15","author":"Hillner","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF31","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1056\/NEJM198011133032010","article-title":"Immunotherapy of malignant melanoma","volume":"303","author":"Terry","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1053\/ctrv.1999.0163_RF32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0959-8049(93)90064-M","article-title":"Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC PROTOCOL 18781)","volume":"29A","author":"Czarnetzki","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1053\/ctrv.1999.0163_RF33","first-page":"744","article-title":"Adjuvant BCG immunotherapy of malignant melanoma","volume":"131","author":"Paterson","year":"1984","journal-title":"Can Med Assoc J"},{"key":"10.1053\/ctrv.1999.0163_RF34","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0039-6109(16)42582-X","article-title":"Adjuvant immunotherapy or chemotherapy for malignant melanoma: preliminary report of the National Cancer Institute randomised clinical trial","volume":"61","author":"Fisher","year":"1981","journal-title":"Surg Clin North Am"},{"key":"10.1053\/ctrv.1999.0163_RF35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM198210073071503","article-title":"A randomised trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma","volume":"307","author":"Veronesi","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1053\/ctrv.1999.0163_RF36","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/1097-0142(19820315)49:6<1079::AID-CNCR2820490604>3.0.CO;2-X","article-title":"A randomised prospective clinical trial of adjuvant C.parvum immunotherapy in 260 patients with clinically localised melanoma (stage I)","volume":"49","author":"Balch","year":"1982","journal-title":"Cancer"},{"key":"10.1053\/ctrv.1999.0163_RF37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/1097-0142(19830115)51:2<269::AID-CNCR2820510217>3.0.CO;2-6","article-title":"Randomised controlled trial of transfer factor in stage II malignant melanoma","volume":"51","author":"Bukowski","year":"1983","journal-title":"Cancer"},{"key":"10.1053\/ctrv.1999.0163_RF38","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.1991.9.5.729","article-title":"Improved survival in patients with poor prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the national cancer institute of Canada clinical trials group","volume":"9","author":"Quirt","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF39","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1200\/JCO.1991.9.5.736","article-title":"A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma","volume":"9","author":"Spitler","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF40","first-page":"611","article-title":"Active Immunotherapy with allogeneic tumour cell vaccines: Present status","volume":"25","author":"Chan","year":"1998","journal-title":"Seminars in Oncology"},{"key":"10.1053\/ctrv.1999.0163_RF41","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/jnci\/85.13.1080","article-title":"Randomised trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high risk, multinode positive malignant melanoma","volume":"85","author":"Meisenberg","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/ctrv.1999.0163_RF42","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1200\/JCO.1994.12.5.1036","article-title":"Improved survival in stage III melanoma patients with GM2 antibodies: a randomised trial of adjuvant vaccination with GM2 ganglioside","volume":"12","author":"Livingstone","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.1999.0163_RF43","series-title":"Cancer: Principles and Practice of Oncology.","first-page":"1947","article-title":"Cutaneous melanoma","author":"Balch","year":"1997"},{"key":"10.1053\/ctrv.1999.0163_RF44","unstructured":"Personal communication, Gore, M."},{"key":"10.1053\/ctrv.1999.0163_RF45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(96)02482-8","article-title":"Benefits from specialised cancer care","volume":"348","author":"Selby","year":"1996","journal-title":"Lancet"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737299901639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737299901639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T06:16:11Z","timestamp":1621145771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737299901639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,4]]}},"alternative-id":["S0305737299901639"],"URL":"https:\/\/doi.org\/10.1053\/ctrv.1999.0163","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2000,4]]}}}